Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can ACAT inhibition limit the progression of atherosclerosis in patients with coronary artery disease?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 366–367 (2006)Cite this article

boxed-textNissen SE et al. (2006) Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354: 1253–1263

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Heinonen TM (2002) Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis? Curr Atheroscler Rep 4: 65–70

    Article  Google Scholar 

  2. Guedes A and Tardif JC (2004) Intravascular ultrasound assessment of atherosclerosis. Curr Atheroscler Rep 6: 219–224

    Article  Google Scholar 

  3. Tardif JC et al. (2004) Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110: 3372–3377

    Article  CAS  Google Scholar 

  4. Fazio S et al. (2001) Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 107: 163–171

    Article  CAS  Google Scholar 

  5. Jensen LO et al. (2004) Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 110: 265–270

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Medicine, Montreal Heart Institute,

    Jean-Claude Tardif

  2. Université de Montréal, QC, Canada

    Jean-Claude Tardif

  3. Associate Director for scientific affairs at the Montreal Heart Institute Coordinating Center,

    Therese Heinonen

Authors
  1. Jean-Claude Tardif
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Therese Heinonen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Claude Tardif.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tardif, JC., Heinonen, T. Can ACAT inhibition limit the progression of atherosclerosis in patients with coronary artery disease?. Nat Rev Cardiol 3, 366–367 (2006). https://doi.org/10.1038/ncpcardio0599

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0599

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing